Hercules, CA — November 20, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its S3e Cell Sorter that offers walk-away automation for accurate and reliable cell sorts of one or two populations.
The S3e Cell Sorter builds on the original S3™ Cell Sorter technology with the addition of the new AutoGimbal System. This novel automated system perfectly aligns the nozzle tip and stream to the optics, eliminating the need for manual repositioning. The AutoGimbal System makes these fine adjustments using five motorized controllers. Researchers can now be more confident that their system is set up correctly every time.
Traditionally, researchers have sorted cells at a core lab due to high instrument and operating costs, as well as the need for a trained core staff specialist to help run the sort. The arrival of the affordable and first walk-away S3e Cell Sorter enables labs to have their own personal cell sorter. The simple setup and hands-free calibration eliminate the pain points of typical high-end instruments, making cell sorting easier and accessible to researchers who are increasingly using these instruments for low-complexity sorts.
Additional benefits of the S3e Cell Sorter include:
- Simplified setup — fully automated drop delay calculation and droplet break-off monitoring enable precise sorting with minimal training
- Small benchtop footprint — onboard fluidics and temperature control allow a compact size (2.3 x 2.1 x 2.1 ft)
- Two-way cell sorting — sort two different defined populations at the same time with one or two lasers and up to four fluorescent detectors
- High speed and high purity — sort cells quickly while maintaining high sensitivity and purity
For more information, please visit www.bio-rad/S3ePR for the S3e and other available Bio-Rad cell sorters.
About the Cell Biology Portfolio
The cell biology product portfolio from Bio-Rad Laboratories comprises solutions for researchers conducting experiments that involve cell culture, cellular imaging, and cell analysis. Bio-Rad is a well-established provider of transfection tools, particularly through its line of Gene Pulser® Electroporation Systems. The company has expanded its cell biology offerings to include the S3e™ Cell Sorter, the ZOE™ Fluorescent Cell Imager, and the TC20™ Automated Cell Counter. These instruments are supported by a suite of flow cytometry and fluorescent cell imaging reagents, including ReadiLink Antibody Labeling Kits. In addition, more than 10,500 antibodies and associated kits and accessories are available for various cell biology applications from AbD Serotec, a Bio-Rad company. Visit www.bio-rad.com/lifescience for more information.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs more than 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. Visit us at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Steve Kulisch
Bio-Rad
510-741-6688
Steve_Kulisch@bio-rad.com
Chempetitive Group
312-997-2436 x112
kli@chempetitive.com